The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organization championing the benefits of engineered cell therapies and genetic medicines for patients, healthcare systems, and society. As a community, ARM builds the future of medicine by convening the sector, facilitating influential exchanges on policies and practices, and advancing the narrative with data and analysis. We actively engage key stakeholders to enable the development of advanced therapies and to modernize healthcare systems so that patients benefit from durable, potentially curative treatments. As the global voice of the sector, we represent more than 400 members across 25 countries, including emerging and established biotechnology companies, academic and medical research institutions, and patient organizations. To learn more about ARM or to become a member, visit http://www.alliancerm.org.
After decades of investigation, scientists have unlocked the power of our body’s own immune system to fight cancer. This class of treatments—called cancer immunotherapy—enhances a patient’s immune system to identify and eliminate cancer cells, anywhere in the body.
Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization that is dedicated to saving more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer.
We fund the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. CRI’s programs provide strategic support along the entire pathway of discovery, drug development, and patient support.
To learn more, visit https://www.cancerresearch.org/
For decades, entrenched infrastructure barriers have slowed progress in the fight against cancer and the development of potent immunotherapies. The Parker Institute for Cancer Immunotherapy breaks down these barriers and focuses fully on this durable and promising treatment. The result is groundbreaking new research and an intellectual property model that builds collaboration between researchers, nonprofits and industry all working together to get treatments to patients faster. To learn more, please visit https://www.parkerici.org/
Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a not-for-profit organization of medical professionals dedicated to improving patient outcomes by advancing the development, science and application of cancer immunotherapy. As the world’s leading member-driven organization dedicated to cancer immunotherapy and tumor immunology, SITC is comprised of more than 4,650 influential basic and translational scientists, clinicians, health care professionals, government leaders and industry professionals from around the globe. For more information about SITC, please visit https://www.sitcancer.org/home.
The Journal of Immunotherapy and Precision Oncology (JIPO) is a peer-reviewed open-access journal published quarterly since 2018. JIPO aims to publish high-quality articles that appeal to a broad readership of healthcare professionals and scientists, especially those with an interest in immunotherapy and precision oncology. Topics in the Journal include studies of immune system function and biology, new therapeutic approaches to different malignancies, mechanisms of resistance, clinical assessment, prognostic or predictive markers, targeted therapy, and more. Please visit jipoonline.org to learn more and submit a manuscript.
Established in 1983, the Center for Biotechnology (CFB) at Stony Brook University is an Empire State Development Division of Science, Technology and Innovation (NYSTAR) Center for Advanced Technology and NIH-designated Research, Evaluation and Commercialization Hub (REACH).
The Center for Biotechnology serves as an important catalyst in the development of new biomedical technologies and emerging companies in New York State. Through groundbreaking initiatives, the Center supports technology commercialization and company formation by bridging the gap between discovery and commercial success, and by training the next generation of biomedical leaders. The Center for Biotechnology also supports New York’s biotechnology industry by providing access to scientific and business expertise and creating strategic infrastructure that promotes the growth of the life sciences industry in the State. The Center for Biotechnology has contributed to the development of more than a dozen FDA approved products including ReoPro®, Xiaflex®, Oracea®, Cavistat®, V3D®-Colon Virtual Colonoscopy and Exogen® Bone Healing System, among others, as well as supported the formation or development of dozens of emerging bioscience companies. Learn more at https://centerforbiotechnology.org/
Greater Gift started in 2010 with a simple idea: celebrate the patients in clinical trials and the research professionals who support them in order to reinforce the impact of their participation in research. Our mission has grown through our celebration and community outreach programs to increase awareness of clinical research, especially among underrepresented communities. Greater Gift works to ensure all ethnic, racial, and marginalized populations are represented equally in research, so that medicines, treatments, and medical devices are effective for everyone. To learn more, please visit http://greatergift.org/
Big4Bio is the premier aggregator of news and developments in the life sciences sector. Our name stands for the cornerstone “Big 4” in biosciences and health: drugs, devices, diagnostics, and digital (also known as the “four D’s”), and our free, daily email newsletters give readers easy-to-scan headlines to “Big 4” content gleaned from thousands of industry sources. We produce individual summaries for the most significant life sciences markets in the world: Boston, San Francisco Bay Area, San Diego, Philadelphia, DC/VA/MD region (Capital Region), New York City, Los Angeles, and Seattle. To learn more, visit big4bio.com
Pharma Tech Outlook is a monthly publication that has been a pioneer in bringing forth real-world solutions, news, product trends, solutions, and many more to subscribers. The unique learn-from-peers approach is creating a difference since the decision-makers are constantly sharing their experience, wisdom and thought leadership with each other. Pharma Tech Outlook has contributors from the most established organizations and institutions who have been presenting their viewpoints using this unique print platform. The magazine has been incorporated by some seasoned industry experts and has been at the forefront of presenting a comprehensive and detailed view of the technology arena. Pharma Tech Outlook aims at contributing to the transformation of innovations into services as well as creating a healthy and productive ecosystem. To learn more, please visit https://www.pharmatechoutlook.com/